Novartis Aktie

78,49EUR
+0,01EUR
+0,01%
15:46:17
82,13CHF
-0,32CHF
-0,39%
15:39:00

WKN: 904278 / ISIN: CH0012005267

  Kaufen  
Verkaufen
oder
Werbung

Novartis Aktien News

14.01.22
Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief (Zacks)
11.01.22
Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug (Zacks)
10.01.22
Novartis to seek speedy approval for Covid drug after positive trials (Financial Times)
10.01.22
Dow Jones Newswires: Novartis to seek FDA approval for COVID-19 treatment after positive data (MarketWatch)
10.01.22Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 (GlobeNewswire)
10.01.22
NOVARTIS AG CHF0.50(REGD) : Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 (Investegate)
07.01.22
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies (Zacks)
04.01.22Press Release: Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya(R) (fingolimod) dosage regimen patent (Dow Jones)
04.01.22Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent (GlobeNewswire)
04.01.22
NOVARTIS AG CHF0.50(REGD) : Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent (Investegate)
28.12.21
Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption (Zacks)
23.12.21
Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion (Zacks)
23.12.21
Novartis Eyes Up to $1.5 Billion for Gene Therapy Firm (MotleyFool)
23.12.21Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis (GlobeNewswire)
22.12.21FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year (GlobeNewswire)
22.12.21
Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA (Zacks)
22.12.21
The Wall Street Journal: Novartis to purchase British biotech Gyroscope, a gene-therapy company (MarketWatch)
22.12.21Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness (GlobeNewswire)
22.12.21Press Release: Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause o... (Dow Jones)
22.12.21Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA (GlobeNewswire)
22.12.21Press Release: Novartis: Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA (Dow Jones)
22.12.21
NOVARTIS AG CHF0.50(REGD) : Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness (Investegate)
21.12.21
Novartis (NVS) Collaborates With BeiGene for Oncology Drug (Zacks)
20.12.21Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA (GlobeNewswire)
20.12.21Press Release: Novartis: Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA (Dow Jones)
20.12.21
Here's Why You Should Hold on to Alcon (ALC) Stock for Now (Zacks)
20.12.21
BeiGene to receive up to $1 billion in oncology deal with Novartis (Market Watch)
20.12.21Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab (GlobeNewswire)
20.12.21Press Release: Novartis strengthens immunotherapy -2- (Dow Jones)
20.12.21
NOVARTIS AG CHF0.50(REGD) : Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab (Investegate)
20.12.21Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) (GlobeNewswire)
20.12.21Press Release: Novartis provides an update on -2- (Dow Jones)
20.12.21
NOVARTIS AG CHF0.50(REGD) : Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) (Investegate)
16.12.21
Alcon (ALC) on Track With Successful Global PRECISION1 Rollout (Zacks)
16.12.21Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
16.12.21Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (GlobeNewswire)
16.12.21
NOVARTIS AG CHF0.50(REGD) : Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline (Investegate)
14.12.21
‘Heads down and working’: Mesoblast boss unfazed as Novartis deal ends (The Sydney Morning Herald)
13.12.21Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021 (GlobeNewswire)
11.12.21Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia (GlobeNewswire)
Seite: 123456789...25

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung
finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln